
  
    
      
        Introduction_NNP
        Somatic_NNP gain-of-function_JJ mutations_NNS in_IN exons_NNS encoding_VBG the_DT epidermal_NN growth_NN factor_NN
        receptor_NN (_( EGFR_NNP )_) tyrosine_NN kinase_NN domain_NN are_VBP found_VBN in_IN about_IN 10_CD %_NN of_IN non-small_JJ cell_NN lung_NN
        cancers_NNS (_( NSCLCs_NNP )_) from_IN the_DT United_NNP States_NNPS [_NN 1_CD ,_, 2_CD ,_, 3_CD ]_NN ,_, with_IN higher_JJR percentages_NNS observed_VBD in_IN east_JJ
        Asia_NNP [_NN 2_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ]_NN ._. Some_DT 90_CD %_NN of_IN NSCLC-associated_NNP mutations_NNS occur_VBP as_IN either_DT multi-nucleotide_JJ
        in-frame_JJ deletions_NNS in_IN exon_NN 19_CD ,_, involving_VBG elimination_NN of_IN four_CD amino_JJ acids_NNS ,_, Leu-_NNP Arg-_NNP Glu-_NNP Ala_NNP ,_,
        or_CC as_IN a_DT single_JJ nucleotide_NN substitution_NN at_IN nucleotide_NN 2573_CD (_( T_NN →_NN G_NNP )_) in_IN exon_NN 21_CD ,_, resulting_VBG in_IN
        substitution_NN of_IN arginine_NN for_IN leucine_NN at_IN position_NN 858_CD (_( L_NNP 858_CD R_NN )_) ._. Both_DT of_IN these_DT mutations_NNS are_VBP
        associated_VBN with_IN sensitivity_NN to_TO the_DT small-molecule_JJ kinase_NN inhibitors_NNS gefitinib_NN or_CC erlotinib_NN
        [_NN 1_CD ,_, 2_CD ,_, 3_CD ]_NN ._. Unfortunately_RB ,_, nearly_RB all_DT patients_NNS who_WP experience_NN marked_VBD improvement_NN on_IN these_DT
        drugs_NNS eventually_RB develop_VBP progression_NN of_IN disease_NN ._. While_IN 
        KRAS_NNP mutations_NNS have_VBP been_VBN associated_VBN with_IN some_DT cases_NNS of_IN primary_JJ resistance_NN
        to_TO gefitinib_NN or_CC erlotinib_NN [_NN 7_CD ]_NN ,_, mechanisms_NNS underlying_VBG “ acquired_VBN” or_CC “ secondary_JJ” resistance_NN
        are_VBP unknown_JJ ._.
        Acquired_VBN resistance_NN to_TO kinase-targeted_JJ anticancer_NN therapy_NN has_VBZ been_VBN most_RBS extensively_RB
        studied_VBN with_IN imatinib_NN ,_, an_DT inhibitor_NN of_IN the_DT aberrant_NN BCR-ABL_NNP kinase_NN ,_, in_IN chronic_JJ myelogenous_JJ
        leukemia_NN (_( CML_NNP )_) ._. Mutations_NNP in_IN the_DT ABL_NNP kinase_NN domain_NN are_VBP found_VBN in_IN 50_CD %_NN –_NN 90_CD %_NN of_IN patients_NNS with_IN
        secondary_JJ resistance_NN to_TO the_DT drug_NN (_( reviewed_VBN in_IN [_NN 8_CD ]_NN )_) ._. Such_JJ mutations_NNS ,_, which_WDT cluster_NN in_IN four_CD
        distinct_JJ regions_NNS of_IN the_DT ABL_NNP kinase_NN domain_NN (_( the_DT ATP_NNP binding_JJ loop_NN ,_, T_NN 315_CD ,_, M_NNP 351_CD ,_, and_CC the_DT
        activation_NN loop_NN )_) ,_, interfere_VB with_IN binding_JJ of_IN imatinib_NN to_TO ABL_NNP [_NN 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. Crystallographic_NNP
        studies_NNS of_IN various_JJ ABL_NNP mutants_NNS predict_VBP that_IN most_JJS should_MD remain_VB sensitive_JJ to_TO inhibitors_NNS that_WDT
        bind_NN ABL_NNP with_IN less_RBR stringent_JJ structural_JJ requirements_NNS ._. Using_VBG this_DT insight_NN ,_, new_JJ
        small-molecule_JJ inhibitors_NNS have_VBP been_VBN identified_VBN that_WDT retain_VBP activity_NN against_IN the_DT majority_NN of_IN
        imatinib-resistant_JJ BCR-ABL_NNP mutants_NNS [_NN 12_CD ,_, 13_CD ]_NN ._.
        Although_IN imatinib_NN inhibits_NNS different_JJ kinases_NNS in_IN various_JJ diseases_NNS (_( BCR-ABL_NNP in_IN CML_NNP ,_, KIT_NNP or_CC
        PDGFR-alpha_NNP in_IN gastrointestinal_NN stromal_NN tumors_NNS [_NN GISTs_NNP ]_NN ,_, and_CC PDGFR-alpha_NNP in_IN
        hypereosinophilic_JJ syndrome_NN [_NN HES_NNP ]_NN )_) (_( reviewed_VBN in_IN [_NN 14_CD ]_NN )_) ,_, some_DT tumors_NNS that_WDT become_VBP refractory_JJ to_TO
        treatment_NN with_IN imatinib_NN appear_VBP to_TO have_VB analogous_JJ secondary_JJ mutations_NNS in_IN the_DT kinase-coding_JJ
        domain_NN of_IN the_DT genes_NNS encoding_VBG these_DT three_CD enzymes_NNS ._. For_IN example_NN ,_, in_IN CML_NNP ,_, a_DT commonly_RB found_VBN
        mutation_NN is_VBZ a_DT C_NNP →_NN T_NN single_JJ nucleotide_NN change_NN that_WDT replaces_VBZ threonine_NN with_IN isoleucine_NN at_IN
        position_NN 315_CD (_( T_NN 315_CD I_PRP )_) in_IN the_DT ABL_NNP kinase_NN domain_NN [_NN 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. In_IN GIST_NNP and_CC HES_NNP ,_, respectively_RB ,_, the_DT
        analogous_JJ T_NN 670_CD I_PRP mutation_NN in_IN KIT_NNP and_CC T_NN 674_CD I_PRP mutation_NN in_IN PDGFR-alpha_NNP have_VBP been_VBN associated_VBN with_IN
        acquired_VBN resistance_NN to_TO this_DT drug_NN [_NN 15_CD ,_, 16_CD ]_NN ._.
        To_TO determine_VB whether_IN lung_NN cancers_NNS that_WDT acquire_NN clinical_JJ resistance_NN to_TO either_CC gefitinib_NN
        or_CC erlotinib_NN display_NN additional_JJ mutations_NNS in_IN the_DT EGFR_NNP kinase_NN domain_NN ,_, we_PRP have_VBP examined_VBN the_DT
        status_NN of_IN 
        EGFR_NNP exons_NNS 18_CD to_TO 24_CD in_IN tumors_NNS from_IN five_CD patients_NNS who_WP initially_RB responded_VBD
        but_CC subsequently_RB progressed_VBD while_IN on_IN these_DT drugs_NNS ._. These_DT exons_NNS were_VBD also_RB assessed_VBN in_IN tumor_NN
        cells_NNS from_IN a_DT sixth_JJ patient_NN whose_WP$ disease_NN rapidly_RB recurred_JJ while_IN on_IN gefitinib_NN therapy_NN after_IN
        complete_JJ gross_JJ tumor_NN resection_NN ._. Because_IN of_IN the_DT association_NN of_IN 
        KRAS_NNP mutations_NNS with_IN primary_JJ resistance_NN to_TO gefitinib_NN and_CC erlotinib_NN [_NN 7_CD ]_NN ,_, we_PRP
        also_RB examined_VBD the_DT status_NN of_IN 
        KRAS_NNP in_IN tumor_NN cells_NNS from_IN these_DT six_CD patients_NNS ._. In_IN an_DT effort_NN to_TO explain_VB the_DT
        selective_JJ advantage_NN of_IN cells_NNS with_IN a_DT newly_RB identified_VBN “ resistance_NN” mutation_NN in_IN 
        EGFR—_NNP a_DT T_NN 790_CD M_NNP amino_JJ acid_NN substitution—we_NN further_RBR characterized_VBD the_DT drug_NN
        sensitivity_NN of_IN putatively_RB resistant_JJ EGFR_NNP mutants_NNS versus_CC wild-type_JJ or_CC drug-sensitive_JJ EGFR_NNP
        mutants_NNS ,_, using_VBG both_DT a_DT NSCLC_NNP cell_NN line_NN fortuitously_RB found_VBD to_TO contain_VB the_DT T_NN 790_CD M_NNP mutation_NN and_CC
        lysates_NNS from_IN cells_NNS transiently_RB transfected_JJ with_IN wild-type_JJ and_CC mutant_JJ 
        EGFR_NNP cDNAs_NNS ._.
      
      
        Methods_NNP
        
          Tissue_NNP Procurement_NNP
          Tumor_NNP specimens_NNS ,_, including_VBG paraffin_NN blocks_NNS ,_, fine_NN needle_NN biopsies_NNS ,_, and_CC pleural_NN
          effusions_NNS ,_, were_VBD obtained_VBN through_IN protocols_NNS approved_VBN by_IN the_DT Institutional_NNP Review_NNP Board_NNP of_IN
          Memorial_NNP Sloan-_NNP Kettering_NNP Cancer_NNP Center_NNP (_( protocol_NN 92_CD –_NN 055_CD [_NN 7_CD ]_NN and_CC protocol_NN 04_CD –_NN 103_CD [_NN Protocol_NNP
          S_NNP 1_CD ]_NN )_) ._. All_DT patients_NNS provided_VBN informed_VBN consent_NN ._.
        
        
          Mutational_NNP Analyses_NNS of_IN EGFR_NNP and_CC KRAS_NNP in_IN Lung_NNP Tumors_NNP
          Genomic_NNP DNA_NNP was_VBD extracted_VBN from_IN tumor_NN specimens_NNS ,_, and_CC primers_NNS for_IN 
          EGFR_NNP (_( exons_NNS 18_CD –_NN 24_CD )_) and_CC 
          KRAS_NNP 2_CD (_( exon_NN 2_LS )_) analyses_NNS were_VBD as_IN published_VBN [_NN 3_CD ,_, 7_CD ]_NN ._. All_DT sequencing_VBG
          reactions_NNS were_VBD performed_VBN in_IN both_DT forward_RB and_CC reverse_VB directions_NNS ,_, and_CC all_DT mutations_NNS were_VBD
          confirmed_VBN at_IN least_JJS twice_RB from_IN independent_JJ PCR_NNP isolates_VBZ ._.
          A_DT specific_JJ exon_NN 20_CD mutation_NN (_( T_NN 790_CD M_NNP )_) was_VBD also_RB detected_VBN by_IN length_NN analysis_NN of_IN
          fluorescently_RB labeled_VBN (_( FAM_NNP )_) PCR_NNP products_NNS on_IN a_DT capillary_JJ electrophoresis_NNS device_NN (_( ABI_NNP 3100_CD
          Avant_NNP ,_, Applied_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ,_, based_VBN on_IN a_DT new_JJ NlaIII_NNP
          restriction_NN site_NN created_VBN by_IN the_DT T_NN 790_CD M_NNP mutation_NN (_( 2369_CD C_NNP →_NN T_NN )_) ,_, using_VBG the_DT following_JJ primers_NNS :_:
          EGFR_NNP Ex_NNP 20_CD F_NN ,_, 5_CD ′_NN -_: FAM-_NNP CTCCCTCCAGGAAGCCTACGTGAT-_NNP 3_CD ′_NN and_CC EGFR_NNP Ex_NNP 20_CD R_NN 5_CD ′_NN -_:
          TTTGCGATCTGCACACACCA-_NNP 3_CD ′_NN ._. Using_VBG serially_RB mixed_JJ dilutions_NNS of_IN DNA_NNP from_IN NSCLC_NNP cell_NN lines_NNS
          (_( H_NNP 1975_CD ,_, L_NNP 858_CD R-_NNP and_CC T_NN 790_CD M-_NNP positive_JJ ;_: H-_NNP 2030_CD ,_, 
          EGFR_NNP wild-type_JJ )_) for_IN calibration_NN ,_, this_DT assay_NN detects_NNS the_DT presence_NN of_IN the_DT
          T_NN 790_CD M_NNP mutation_NN when_WRB H_NNP 1975_CD DNA_NNP comprises_VBZ 3_CD %_NN or_CC more_JJR of_IN the_DT total_JJ DNA_NNP tested_VBD ,_, compared_VBN to_TO a_DT
          sensitivity_NN of_IN 6_CD %_NN for_IN direct_JJ sequencing_VBG (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          RT-PCR_NNP
          The_DT following_VBG primers_NNS were_VBD used_VBN to_TO generate_VB 
          EGFR_NNP cDNA_NN fragments_NNS spanning_VBG exon_NN 20_CD :_: EGFR_NNP 2095_CD F_NN 5_CD ′_NN -_:
          CCCAACCAAGCTCTCTTGAG-_NNP 3_CD ′_NN and_CC EGFR_NNP 2943_CD R_NN 5_CD ′_NN -_: ATGACAAGGTAGCGCTGGGGG-_NNP 3_CD ′_NN ._. PCR_NNP products_NNS were_VBD
          ligated_JJ into_IN plasmids_NNS using_VBG the_DT TOPO_NNP TA-cloning_NNP kit_NN (_( Invitrogen_NNP ,_, Carlsbad_NNP ,_, California_NNP ,_,
          United_NNP States_NNPS )_) ,_, as_IN per_IN manufacturer_NN 's_POS instructions_NNS ._. Minipreps_NNP of_IN DNA_NNP from_IN individual_JJ
          clones_NNS were_VBD sequenced_JJ using_VBG the_DT T_NN 7_CD priming_VBG site_NN of_IN the_DT cloning_VBG vector_NN ._.
        
        
          Functional_NNP Analyses_NNS of_IN Mutant_NNP EGFRs_NNP
          Two_CD numbering_VBG systems_NNS are_VBP used_VBN for_IN EGFR_NNP ._. The_DT first_JJ denotes_NNS the_DT initiating_VBG methionine_NN
          in_IN the_DT signal_NN sequence_NN as_IN amino_JJ acid_NN −_NN 24_CD ._. The_DT second_NN ,_, used_VBD here_RB ,_, denotes_NNS the_DT methionine_NN
          as_IN amino_JJ acid_NN +_NN 1_CD ._. Commercial_JJ suppliers_NNS of_IN antibodies_NNS ,_, such_JJ as_IN the_DT Y_NNP 1068_CD -_: specific_JJ
          anti-phospho-_JJ EGFR_NNP ,_, use_NN the_DT first_JJ nomenclature_NN ._. To_TO be_VB consistent_JJ ,_, we_PRP consider_VBP Y_NNP 1068_CD as_IN
          Y_NNP 1092_CD ._. Likewise_RB ,_, the_DT T_NN 790_CD M_NNP mutation_NN reported_VBD here_RB has_VBZ also_RB been_VBN called_VBN T_NN 766_CD M_NNP ._. Mutations_NNP
          were_VBD introduced_VBN into_IN full-length_JJ wild-type_JJ and_CC mutant_JJ 
          EGFR_NNP cDNAs_NNS using_VBG a_DT QuikChange_NNP Site-_NNP Directed_NNP Mutagenesis_NNP Kit_NNP
          (_( Stratagene_NNP ,_, La_NNP Jolla_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) and_CC cloned_VBN into_IN expression_NN vectors_NNS as_IN
          described_VBN [_NN 3_CD ]_NN ._. The_DT following_VBG primers_NNS were_VBD used_VBN to_TO generate_VB the_DT deletion_NN (_( del_FW )_)
          L_NNP 747_CD –_NN E_NNP 749_CD ;_: A_DT 750_CD P_NN mutant_JJ :_: forward_RB 5_CD ′_NN -_: TAAAATTCCCGTCGCTATCAAGGAGCCAACATCTCCGAAAGCCAACAAGG-_NNP 3_CD ′_NN
          and_CC reverse_VB 5_CD ′_NN -_: CCTTGTTGGCTTTCGGAGATGTTGGCTCCTTGATAGCGACGGGAATTTTA-_NNP 3_CD ′_NN ._. The_DT following_VBG
          primers_NNS were_VBD used_VBN to_TO introduce_VB the_DT T_NN 790_CD M_NNP mutation_NN :_: forward_RB 5_CD ′_NN -_: AGCTCATCATGCAGCTCAT-_NNP 3_CD ′_NN and_CC
          reverse_VB 5_CD ′_NN -_: ATGAGCTGCATGATGAGCT-_NNP 3_CD ′_NN ._. The_DT L_NNP 858_CD R_NN mutant_JJ cDNA_NN was_VBD generated_VBN previously_RB [_NN 3_CD ]_NN ._.
          All_DT mutant_JJ clones_NNS were_VBD fully_RB re-sequenced_JJ bidirectionally_RB to_TO ensure_VB that_IN no_DT additional_JJ
          mutations_NNS were_VBD introduced_VBN ._. Various_JJ EGFRs_NNP were_VBD transiently_RB expressed_VBN in_IN 293_CD T_NN human_JJ
          embryonic_JJ kidney_NN cells_NNS as_IN published_VBN [_NN 3_CD ]_NN ._. Cells_NNP were_VBD treated_VBN with_IN different_JJ concentrations_NNS
          of_IN gefitinib_NN or_CC erlotinib_NN ._.
        
        
          Immunoblotting_NNP
          See_VB Methods_NNP and_CC supplementary_JJ methods_NNS in_IN [_NN 3_CD ]_NN for_IN details_NNS on_IN cell_NN lysis_NNS ,_,
          immunoblotting_VBG ,_, and_CC antibody_NN reagents_NNS ._. At_IN least_JJS three_CD independent_JJ experiments_NNS were_VBD
          performed_VBN for_IN all_DT analyses_NNS ._.
        
        
          Cell_NNP Culture_NNP
          The_DT NSCLC_NNP cell_NN lines_NNS H_NNP 1650_CD ,_, H_NNP 1975_CD ,_, H_NNP 2030_CD ,_, H_NNP 2347_CD ,_, H_NNP 2444_CD ,_, H_NNP 358_CD ,_, and_CC H_NNP 1734_CD were_VBD purchased_VBN
          from_IN American_NNP Type_NNP Culture_NNP Collection_NNP (_( Manassas_NNP ,_, Virginia_NNP ,_, United_NNP States_NNPS )_) ._. H_NNP 3255_CD was_VBD a_DT
          gift_NN of_IN B_NNP ._. Johnson_NNP and_CC P_NN ._. Janne_NNP ._. Cells_NNP were_VBD grown_VBN in_IN complete_JJ growth_NN medium_NN (_( RPMI-_NNP 1640_CD ;_:
          American_NNP Type_NNP Culture_NNP Collection_NNP catalog_NN no_UH ._. 30_CD –_NN 2001_CD )_) supplemented_JJ with_IN 10_CD %_NN fetal_JJ calf_NN
          serum_NN ,_, 10_CD units_NNS /_NN ml_NN penicillin_NN ,_, and_CC 10_CD μg_NN /_NN ml_NN streptomycin_NN )_) at_IN 37_CD °_NN C_NNP and_CC 5_CD %_NN CO_NNP
          2_CD ._. For_IN viability_NN studies_NNS ,_, cells_NNS were_VBD seeded_VBN in_IN complete_JJ growth_NN medium_NN
          in_IN black_JJ 96_CD -_: well_RB clear_JJ bottom_NN ViewPlates_NNP (_( PerkinElmer_NNP ,_, Wellesley_NNP ,_, Massachusetts_NNP ,_, United_NNP
          States_NNPS )_) at_IN a_DT density_NN of_IN 5_CD ,_, 000_CD (_( H_NNP 1975_CD and_CC H_NNP 2030_CD )_) or_CC 7_CD ,_, 500_CD cells_NNS per_IN well_RB (_( H_NNP 3255_CD )_) ._.
          Following_VBG overnight_JJ incubation_NN ,_, cells_NNS were_VBD grown_VBN for_IN 24_CD h_NN in_IN the_DT supplemented_JJ RPMI-_NNP 1640_CD
          medium_NN with_IN 0_CD ._. 1_CD %_NN serum_NN ._. Cells_NNP (_( in_IN supplemented_JJ RPMI-_NNP 1640_CD medium_NN containing_VBG 0_CD ._. 1_CD %_NN serum_NN )_)
          were_VBD then_RB incubated_JJ for_IN 48_CD h_NN in_IN the_DT continued_VBN presence_NN of_IN gefitinib_NN or_CC erlotinib_NN ._.
        
        
          Viability_NNP Assay_NNP
          Cell_NNP viability_NN was_VBD assayed_JJ using_VBG Calcein_NNP AM_NNP (_( acetoxymethyl_NN ester_NN of_IN Calcein_NNP ,_, Molecular_NNP
          Probes_NNP ,_, Eugene_NNP ,_, Oregon_NNP ,_, United_NNP States_NNPS )_) ._. Following_VBG incubation_NN with_IN gefitinib_NN or_CC erlotinib_NN ,_,
          monolayers_NNS were_VBD washed_VBN twice_RB with_IN PBS_NNP (_( containing_VBG calcium_NN and_CC magnesium_NN )_) and_CC incubated_JJ
          with_IN 7_CD ._. 5_CD μmol_NN Calcein_NNP AM_NNP in_IN supplemented_JJ RPMI-_NNP 1640_CD (_( no_DT serum_NN )_) for_IN 30_CD min_NN ._. Labeling_VBG medium_NN
          was_VBD removed_VBN ,_, and_CC cells_NNS were_VBD washed_VBN three_CD times_NNS with_IN PBS_NNP ._. Calcein_NNP fluorescence_NN (_( Ex_NNP ,_, 485_CD
          nm_NN ;_: Em_NNP ,_, 535_CD nM_NN )_) was_VBD detected_VBN immediately_RB using_VBG a_DT Victor_NNP V_NNP multi-label_JJ plate_NN reader_NN
          (_( PerkinElmer_NNP )_) ._. Three_CD independent_JJ experiments_NNS were_VBD performed_VBN for_IN each_DT cell_NN line_NN ;_: each_DT
          experiment_NN included_VBD four_CD to_TO eight_CD replicates_NNS per_IN condition_NN ._.
        
      
      
        Results_NNS
        
          Case_NN Reports_NNPS
          We_PRP identified_VBD secondary_JJ 
          EGFR_NNP mutations_NNS in_IN three_CD of_IN six_CD individuals_NNS whose_WP$ disease_NN progressed_VBD on_IN
          either_DT gefitinib_NN or_CC erlotinib_NN (_( Table_NNP 1_LS )_) ._. Brief_NN case_NN histories_NNS of_IN these_DT three_CD patients_NNS are_VBP
          presented_VBN below_IN ._.
          
            Patient_NNP 1_CD
            This_DT 63_CD -_: y-old_JJ female_JJ “ never_RB smoker_NN” (_( smoked_VBD less_JJR than_IN 100_CD cigarettes_NNS in_IN her_PRP$
            lifetime_NN )_) initially_RB presented_VBN with_IN bilateral_JJ diffuse_NN chest_NN opacities_NNS and_CC a_DT right-sided_JJ
            pleural_NN effusion_NN ._. Transbronchial_NNP biopsy_NN revealed_VBD adenocarcinoma_NN ._. Disease_NNP progressed_VBD on_IN
            two_CD cycles_NNS of_IN systemic_JJ chemotherapy_NN ,_, after_IN which_WDT gefitinib_NN ,_, 250_CD mg_NN daily_NN ,_, was_VBD started_VBN ._.
            Comparison_NNP of_IN chest_NN radiographs_NNS obtained_VBN prior_RB to_TO starting_VBG gefitinib_NN (_( Figure_NNP S_NNP 1_CD A_DT ,_, left_VBD
            panel_NN )_) and_CC 2_CD wk_NN later_RB (_( Figure_NNP S_NNP 1_CD A_DT ,_, middle_JJ panel_NN )_) showed_VBD dramatic_JJ improvement_NN ._. Nine_CD
            months_NNS later_RB ,_, a_DT chest_NN radiograph_NN revealed_VBD progression_NN of_IN disease_NN (_( Figure_NNP S_NNP 1_CD A_DT ,_, right_JJ
            panel_NN )_) ._. Subsequently_RB ,_, the_DT patient_NN underwent_VBD a_DT computed_JJ tomography_NN (_( CT_NNP )_) –_NN guided_VBD biopsy_NN of_IN
            an_DT area_NN in_IN the_DT right_JJ lung_NN base_NN (_( Figure_NN 1_CD A_DT ,_, left_VBD panel_NN )_) ._. Despite_IN continued_JJ treatment_NN
            with_IN gefitinib_NN ,_, either_CC with_IN chemotherapy_NN or_CC at_IN 500_CD mg_NN daily_JJ ,_, the_DT pleural_NN effusion_NN
            recurred_JJ ,_, 12_CD mo_NN after_IN initiating_VBG gefitinib_NN (_( Figure_NN 1_CD A_DT ,_, right_JJ panel_NN )_) ._. Pleural_NNP fluid_NN was_VBD
            obtained_VBN for_IN molecular_JJ studies_NNS ._. In_IN total_JJ ,_, this_DT patient_NN had_VBD three_CD tumor_NN specimens_NNS
            available_JJ for_IN analysis_NN :_: the_DT original_JJ lung_NN tumor_NN biopsy_NN ,_, a_DT biopsy_NN of_IN the_DT progressing_VBG
            lung_NN lesion_NN ,_, and_CC pleural_NN fluid_JJ ._. However_RB ,_, re-review_JJ of_IN the_DT original_JJ transbronchial_NN
            biopsy_NN showed_VBD that_IN it_PRP had_VBD scant_JJ tumor_NN cells_NNS (_( Table_NNP 1_LS )_) ._.
          
          
            Patient_NNP 2_CD ._.
            This_DT 55_CD -_: y-old_JJ woman_NN with_IN a_DT nine_CD pack-year_JJ history_NN of_IN smoking_NN underwent_VBD two_CD surgical_JJ
            resections_NNS within_IN 2_CD y_NN (_( right_NN lower_JJR and_CC left_VBD upper_JJ lobectomies_NNS )_) for_IN bronchioloalveolar_NN
            carcinoma_NN with_IN focal_JJ invasion_NN ._. Two_CD years_NNS later_RB ,_, her_PRP$ disease_NN recurred_JJ with_IN bilateral_JJ
            pulmonary_JJ nodules_NNS and_CC further_RBR progressed_VBD on_IN systemic_JJ chemotherapy_NN ._. Thereafter_RB ,_, the_DT
            patient_NN began_VBD erlotinib_NN ,_, 150_CD mg_NN daily_RB ._. A_DT baseline_JJ CT_NNP scan_VB of_IN the_DT chest_NN demonstrated_VBD
            innumerable_JJ bilateral_JJ nodules_NNS (_( Figure_NNP S_NNP 1_CD B_NNP ,_, left_VBD panel_NN )_) ,_, which_WDT were_VBD markedly_RB reduced_VBN in_IN
            number_NN and_CC size_NN 4_CD mo_NN after_IN treatment_NN (_( Figure_NNP S_NNP 1_CD B_NNP ,_, middle_JJ panel_NN )_) ._. After_IN 14_CD mo_NN of_IN
            therapy_NN ,_, the_DT patient_NN 's_POS dose_NN of_IN erlotinib_NN was_VBD decreased_VBN to_TO 100_CD mg_NN daily_JJ owing_VBG to_TO
            fatigue_NN ._. At_IN 23_CD mo_NN of_IN treatment_NN with_IN erlotinib_NN ,_, a_DT CT_NNP scan_VB demonstrated_VBN an_DT enlarging_VBG
            sclerotic_JJ lesion_NN in_IN the_DT thoracic_JJ spine_NN ._. The_DT patient_NN underwent_VBD CT-guided_NNP biopsy_NN of_IN this_DT
            lesion_NN (_( Figure_NN 1_CD B_NNP ,_, left_VBD panel_NN )_) ,_, and_CC the_DT erlotinib_NN dose_NN was_VBD increased_VBN to_TO 150_CD mg_NN daily_RB ._.
            After_IN 25_CD mo_NN of_IN treatment_NN ,_, she_PRP progressed_VBD within_IN the_DT lung_NN (_( Figure_NNP S_NNP 1_CD B_NNP ,_, right_JJ panel_NN )_) ._.
            Erlotinib_NNP was_VBD discontinued_VBN ,_, and_CC a_DT fluoroscopically_RB guided_VBN core_NN needle_NN biopsy_NN was_VBD
            performed_VBN at_IN a_DT site_NN of_IN progressive_JJ disease_NN in_IN the_DT lung_NN (_( Figure_NN 1_CD B_NNP ,_, right_JJ panel_NN )_) ._. In_IN
            total_JJ ,_, this_DT patient_NN had_VBD three_CD tumor_NN specimens_NNS available_JJ for_IN analysis_NN :_: the_DT original_JJ
            resected_JJ lung_NN tumor_NN ,_, the_DT biopsy_NN of_IN the_DT enlarging_VBG spinal_JJ lesion_NN ,_, and_CC the_DT biopsy_NN of_IN the_DT
            progressing_VBG lung_NN lesion_NN (_( Table_NNP 1_LS )_) ._.
          
          
            Patient_NNP 3_CD
            This_DT 55_CD -_: y-old_JJ female_JJ “ never_RB smoker_NN” was_VBD treated_VBN for_IN nearly_RB 4_CD ._. 5_CD y_NN with_IN weekly_JJ
            paclitaxel_NN and_CC trastuzumab_NN [_NN 17_CD ]_NN for_IN adenocarcinoma_NN with_IN bronchioloalveolar_NN carcinoma_NN
            features_NNS involving_VBG her_PRP$ left_JJ lower_JJR lobe_NN ,_, pleura_NN ,_, and_CC mediastinal_NN lymph_NN nodes_NNS ._. Treatment_NNP
            was_VBD discontinued_VBN owing_VBG to_TO fatigue_NN ._. Subsequently_RB ,_, the_DT patient_NN underwent_VBD surgical_JJ
            resection_NN ._. Because_IN of_IN metastatic_JJ involvement_NN of_IN multiple_JJ mediastinal_NN lymph_NN nodes_NNS and_CC
            clinical_JJ features_NNS known_VBN at_IN that_DT time_NN to_TO be_VB predictive_JJ of_IN response_NN to_TO gefitinib_NN (_( female_JJ ,_,
            never_RB smoker_NN ,_, bronchioloalveolar_NN variant_NN histology_NN )_) ,_, she_PRP was_VBD placed_VBN on_IN “ adjuvant_NN”
            gefitinib_NN 1_CD mo_NN later_RB (_( Figure_NNP S_NNP 1_CD C_NNP ,_, left_VBD panel_NN )_) ._. This_DT drug_NN was_VBD discontinued_VBN after_IN 3_CD mo_NN
            when_WRB she_PRP developed_VBD a_DT new_JJ left-sided_JJ malignant_JJ pleural_NN effusion_NN (_( Figure_NNP S_NNP 1_CD C_NNP ,_, middle_JJ
            panel_NN )_) ._. Despite_IN drainage_NN and_CC systemic_JJ chemotherapy_NN ,_, the_DT pleural_NN effusion_NN recurred_JJ 4_CD mo_NN
            later_RB (_( Figure_NNP S_NNP 1_CD C_NNP ,_, right_JJ panel_NN )_) ,_, at_IN which_WDT time_NN pleural_NN fluid_NN was_VBD collected_VBN for_IN
            analysis_NN ._. In_IN total_JJ ,_, this_DT patient_NN had_VBD two_CD clinical_JJ specimens_NNS available_JJ for_IN analysis_NN :_:
            tumor_NN from_IN the_DT surgical_JJ resection_NN and_CC pleural_NN fluid_JJ (_( Table_NNP 1_LS )_) ._.
          
        
        
          Patients_NNS '_POS Tumors_NNP Contain_NNP EGFR_NNP Tyrosine_NNP Kinase_NNP Domain_NNP Mutations_NNP Associated_NNP with_IN
          Sensitivity_NNP to_TO EGFR_NNP Tyrosine_NNP Kinase_NNP Inhibitors_NNP
          We_PRP screened_VBD all_DT available_JJ tumor_NN samples_NNS from_IN these_DT three_CD patients_NNS for_IN previously_RB
          described_VBD drug-sensitive_JJ 
          EGFR_NNP mutations_NNS ,_, by_IN direct_JJ DNA_NNP sequencing_VBG of_IN exons_NNS 19_CD and_CC 21_CD [_NN 3_CD ]_NN ._. Tumor_NNP
          samples_NNS from_IN patient_NN 1_CD showed_VBD a_DT T_NN →_NN G_NNP change_NN at_IN nucleotide_NN 2573_CD ,_, resulting_VBG in_IN the_DT exon_NN 21_CD
          L_NNP 858_CD R_NN amino_JJ acid_NN substitution_NN commonly_RB observed_VBD in_IN drug-responsive_JJ tumors_NNS ._. This_DT mutation_NN
          was_VBD present_JJ in_IN the_DT biopsy_NN material_NN from_IN the_DT progressing_VBG lung_NN lesion_NN (_( Figure_NNP S_NNP 2_CD A_DT ,_, upper_JJ
          panels_NNS )_) and_CC from_IN cells_NNS from_IN the_DT pleural_NN effusion_NN (_( Figure_NNP S_NNP 2_CD A_DT ,_, lower_JJR panels_NNS )_) ,_, both_DT of_IN
          which_WDT on_IN cytopathologic_JJ examination_NN consisted_VBD of_IN a_DT majority_NN of_IN tumor_NN cells_NNS (_( Table_NNP 1_LS )_) ._.
          Interestingly_RB ,_, comparisons_NNS of_IN the_DT tracings_NNS suggest_VBP that_IN an_DT increase_NN in_IN copy_NN number_NN of_IN the_DT
          mutant_JJ allele_NN may_MD have_VB occurred_VBN ._. Specifically_RB ,_, while_IN the_DT ratio_NN of_IN wild-type_JJ (_( nucleotide_NN
          T_NN )_) to_TO mutant_JJ (_( nucleotide_NN G_NNP )_) peaks_NNS at_IN position_NN 2573_CD was_VBD approximately_RB 1_CD :_: 1_CD or_CC 1_CD :_: 2_CD in_IN the_DT
          lung_NN biopsy_NN specimen_NN (_( Figure_NNP S_NNP 2_CD A_DT ,_, upper_JJ panels_NNS )_) ,_, sequencing_VBG of_IN DNA_NNP from_IN the_DT pleural_NN fluid_JJ
          cells_NNS demonstrated_VBD a_DT dominant_JJ mutant_JJ G_NNP peak_NN (_( Figure_NNP S_NNP 2_CD A_DT ,_, lower_JJR panels_NNS )_) ._. Consistent_NNP with_IN
          this_DT ,_, a_DT single_JJ nucleotide_NN polymorphism_NN (_( SNP_NNP )_) noted_VBD at_IN nucleotide_NN 2361_CD (_( A_DT or_CC G_NNP )_)
          demonstrated_VBD a_DT corresponding_JJ change_NN in_IN the_DT ratios_NNS of_IN A_DT :_: G_NNP ,_, with_IN a_DT 1_CD :_: 1_CD ratio_NN in_IN the_DT
          transbronchial_NN biopsy_NN ,_, and_CC a_DT nearly_RB 5_CD :_: 1_CD ratio_NN in_IN the_DT pleural_NN fluid_JJ (_( Figure_NN 2_CD A_DT )_) ._. Notably_RB ,_,
          we_PRP did_VBD not_RB detect_VB the_DT 2573_CD T_NN →_NN G_NNP mutation_NN in_IN the_DT original_JJ transbronchial_NN biopsy_NN specimen_NN
          (_( Table_NNP 1_CD ;_: data_NNS not_RB shown_VBN )_) ._. As_IN stated_VBN above_IN ,_, this_DT latter_JJ specimen_NN contained_VBD scant_JJ tumor_NN
          cells_NNS ,_, most_RBS likely_JJ fewer_JJR than_IN needed_VBN for_IN detection_NN of_IN an_DT 
          EGFR_NNP mutation_NN by_IN direct_JJ sequencing_VBG (_( see_VB [_NN 7_CD ]_NN )_) ._.
          All_DT three_CD specimens_NNS from_IN patient_NN 2_CD ,_, including_VBG the_DT original_JJ lung_NN tumor_NN and_CC the_DT two_CD
          metastatic_JJ samples_NNS from_IN bone_NN and_CC lung_NN ,_, showed_VBD an_DT exon_NN 19_CD deletion_NN involving_VBG elimination_NN
          of_IN 11_CD nucleotides_NNS (_( 2238_CD –_NN 2248_CD )_) and_CC insertion_NN of_IN two_CD nucleotides_NNS ,_, G_NNP and_CC C_NNP (_( Figure_NNP S_NNP 2_CD B_NNP ,_, all_DT
          panels_NNS ;_: Table_NNP 1_LS )_) ._. These_DT nucleotide_NN changes_NNS delete_VB amino_JJ acids_NNS L_NNP 747_CD –_NN E_NNP 749_CD and_CC change_VB amino_JJ
          acid_NN 750_CD from_IN alanine_NN to_TO proline_NN (_( A_DT 750_CD P_NN )_) ._. A_DT del_FW L_NNP 747_CD –_NN E_NNP 749_CD ;_: A_DT 750_CD P_NN mutation_NN was_VBD previously_RB
          reported_VBN with_IN different_JJ nucleotide_NN changes_NNS [_NN 2_CD ]_NN ._. In_IN all_DT samples_NNS from_IN patient_NN 2_CD ,_, the_DT
          wild-type_JJ sequence_NN predominated_JJ at_IN a_DT ratio_NN of_IN about_IN 3_CD :_: 1_CD over_IN the_DT mutant_JJ sequence_NN ._.
          Both_DT of_IN the_DT available_JJ tumor_NN samples_NNS from_IN patient_NN 3_CD contained_VBD a_DT deletion_NN of_IN 15_CD
          nucleotides_NNS (_( 2236_CD –_NN 2250_CD )_) in_IN exon_NN 19_CD (_( Table_NNP 1_CD ;_: data_NNS not_RB shown_VBN )_) ,_, resulting_VBG in_IN elimination_NN of_IN
          five_CD amino_JJ acids_NNS (_( del_FW E_NNP 746_CD –_NN A_DT 750_CD )_) ._. This_DT specific_JJ deletion_NN has_VBZ been_VBN previously_RB reported_VBN
          [_NN 3_CD ]_NN ._. The_DT ratio_NN of_IN mutant_JJ to_TO wild-type_JJ peaks_NNS was_VBD approximately_RB 1_CD :_: 1_CD in_IN both_DT specimens_NNS (_( data_NNS
          not_RB shown_VBN )_) ._.
          Collectively_RB ,_, these_DT results_NNS demonstrate_VBP that_IN tumors_NNS from_IN all_DT three_CD patients_NNS contain_VBP 
          EGFR_NNP mutations_NNS associated_VBN with_IN sensitivity_NN to_TO the_DT tyrosine_NN kinase_NN
          inhibitors_NNS gefitinib_NN and_CC erlotinib_NN ._. In_IN addition_NN ,_, these_DT data_NNS show_VBP that_IN within_IN individual_JJ
          patients_NNS ,_, metastatic_JJ or_CC recurrent_JJ lesions_NNS to_TO the_DT spine_NN ,_, lung_NN ,_, and_CC pleural_NN fluid_JJ contain_VB
          the_DT same_JJ mutations_NNS ._. These_DT latter_JJ observations_NNS support_VBP the_DT idea_NN that_IN relapsing_VBG and_CC
          metastatic_JJ tumor_NN cells_NNS within_IN individuals_NNS are_VBP derived_VBN from_IN original_JJ progenitor_NN
          clones_NNS ._.
        
        
          A_DT Secondary_JJ Missense_NNP Mutation_NNP in_IN the_DT EGFR_NNP Kinase_NNP Domain_NNP Detected_NNP in_IN Lesions_NNP That_DT
          Progressed_NNP while_IN on_IN Treatment_NNP with_IN Either_DT Gefitinib_NNP or_CC Erlotinib_NNP
          To_TO determine_VB whether_IN additional_JJ mutations_NNS in_IN the_DT 
          EGFR_NNP kinase_NN domain_NN were_VBD associated_VBN with_IN progression_NN of_IN disease_NN in_IN these_DT
          patients_NNS ,_, we_PRP performed_VBD direct_JJ sequencing_VBG of_IN all_DT of_IN the_DT exons_NNS (_( 18_CD through_IN 24_CD )_) encoding_VBG the_DT
          EGFR_NNP catalytic_JJ region_NN in_IN the_DT available_JJ tumor_NN specimens_NNS ._.
          Analysis_NNP of_IN patient_NN 1_CD 's_POS pre-gefitinib_JJ specimen_NN ,_, which_WDT contained_VBD scant_JJ tumor_NN cells_NNS
          (_( Table_NNP 1_CD ;_: see_VB above_IN )_) ,_, not_RB surprisingly_RB showed_VBD only_RB wild-type_JJ 
          EGFR_NNP sequence_NN (_( Table_NNP 1_CD ;_: data_NNS not_RB shown_VBN )_) ._. However_RB ,_, careful_JJ analysis_NN of_IN
          the_DT exon_NN 20_CD sequence_NN chromatograms_NNS in_IN both_DT forward_RB and_CC reverse_VB directions_NNS from_IN this_DT
          patient_NN 's_POS lung_NN biopsy_NN specimen_NN obtained_VBN after_IN disease_NN progression_NN on_IN gefitinib_NN
          demonstrated_VBD an_DT additional_JJ small_JJ peak_NN at_IN nucleotide_NN 2369_CD ,_, suggesting_VBG a_DT C_NNP →_NN T_NN mutation_NN
          (_( Figure_NN 2_CD A_DT ,_, upper_JJ panels_NNS ;_: Table_NNP 1_LS )_) ._. This_DT nucleotide_NN change_NN leads_VBZ to_TO substitution_NN of_IN
          methionine_NN for_IN threonine_NN at_IN position_NN 790_CD (_( T_NN 790_CD M_NNP )_) ._. The_DT 2369_CD C_NNP →_NN T_NN mutant_JJ peak_NN was_VBD even_RB more_RBR
          prominent_JJ in_IN cells_NNS from_IN the_DT patient_NN 's_POS pleural_NN fluid_NN ,_, which_WDT were_VBD obtained_VBN after_IN further_JJ
          disease_NN progression_NN on_IN gefitinib_NN (_( Figure_NN 2_CD A_DT ,_, lower_JJR panels_NNS ;_: Table_NNP 1_LS )_) ._. The_DT increase_NN in_IN the_DT
          ratio_NN of_IN mutant_JJ to_TO wild-type_JJ peaks_NNS obtained_VBN from_IN analyses_NNS of_IN the_DT lung_NN specimen_NN and_CC
          pleural_NN fluid_JJ paralleled_JJ the_DT increase_NN in_IN the_DT ratio_NN of_IN the_DT mutant_JJ G_NNP peak_NN (_( leading_VBG to_TO the_DT
          L_NNP 858_CD R_NN mutation_NN )_) to_TO the_DT wild-type_JJ T_NN peak_NN at_IN nucleotide_NN 2573_CD (_( see_VB above_IN ;_: Figure_NNP S_NNP 2_CD A_DT )_) ,_, as_RB
          well_RB as_IN the_DT increase_NN in_IN the_DT ratio_NN of_IN the_DT A_DT :_: G_NNP SNP_NNP at_IN position_NN 2361_CD (_( Figure_NN 2_CD A_DT )_) ._.
          Collectively_RB ,_, these_DT findings_NNS imply_VBP that_IN the_DT exon_NN 20_CD T_NN 790_CD M_NNP mutation_NN was_VBD present_JJ on_IN the_DT
          same_JJ allele_NN as_IN the_DT exon_NN 21_CD L_NNP 858_CD R_NN mutation_NN ,_, and_CC that_IN a_DT subclone_NN of_IN cells_NNS harboring_VBG these_DT
          mutations_NNS emerged_VBD during_IN drug_NN treatment_NN ._.
          In_IN patient_NN 2_CD ,_, the_DT tumor-rich_JJ sample_NN obtained_VBN prior_RB to_TO treatment_NN with_IN erlotinib_NN did_VBD not_RB
          contain_VB any_DT additional_JJ mutations_NNS in_IN the_DT exons_NNS encoding_VBG the_DT 
          EGFR_NNP tyrosine_NN kinase_NN domain_NN (_( Figure_NN 2_CD B_NNP ,_, upper_JJ panels_NNS ;_: Table_NNP 1_LS )_) ._. By_IN
          contrast_NN ,_, her_PRP$ progressing_VBG bone_NN and_CC lung_NN lesions_NNS contained_VBD an_DT additional_JJ small_JJ peak_NN at_IN
          nucleotide_NN 2369_CD ,_, suggesting_VBG the_DT existence_NN of_IN a_DT subclone_NN of_IN tumor_NN cells_NNS with_IN the_DT same_JJ C_NNP →_NN T_NN
          mutation_NN observed_VBD in_IN patient_NN 1_CD (_( Figure_NN 2_CD B_NNP ,_, middle_JJ and_CC lower_JJR panels_NNS ;_: Table_NNP 1_LS )_) ._. The_DT
          relative_JJ sizes_NNS of_IN the_DT 2369_CD T_NN mutant_JJ peaks_NNS seen_VBN in_IN these_DT latter_JJ two_CD samples_NNS appeared_VBD to_TO
          correlate_VBP with_IN the_DT relative_JJ size_NN of_IN the_DT corresponding_JJ peaks_NNS of_IN the_DT exon_NN 19_CD deletion_NN
          (_( Figure_NNP S_NNP 2_CD B_NNP )_) ._. Interestingly_RB ,_, the_DT SNP_NNP at_IN nucleotide_NN 2361_CD (_( A_DT or_CC G_NNP )_) was_VBD detected_VBN in_IN
          specimens_NNS from_IN patient_NN 2_CD before_IN but_CC not_RB after_IN treatment_NN with_IN erlotinib_NN ,_, suggesting_VBG that_IN
          one_CD 
          EGFR_NNP allele_NN underwent_VBD amplification_NN or_CC deletion_NN during_IN the_DT course_NN of_IN
          treatment_NN (_( Figure_NNP S_NNP 2_CD B_NNP )_) ._.
          Patient_NNP 3_CD showed_VBD results_NNS analogous_JJ to_TO those_DT of_IN patient_NN 2_CD ._. A_DT tumor-rich_JJ pre-treatment_JJ
          specimen_NN did_VBD not_RB demonstrate_VB 
          EGFR_NNP mutations_NNS other_JJ than_IN the_DT del_FW E_NNP 746_CD –_NN A_DT 750_CD exon_NN 19_CD deletion_NN ;_:
          specifically_RB ,_, in_IN exon_NN 20_CD ,_, no_DT secondary_JJ changes_NNS were_VBD detected_VBN (_( Figure_NN 2_CD C_NNP ,_, upper_JJ panels_NNS ;_:
          Table_NNP 1_LS )_) ._. However_RB ,_, analysis_NN of_IN DNA_NNP from_IN cells_NNS in_IN the_DT pleural_NN effusion_NN that_WDT developed_VBD
          after_IN treatment_NN with_IN gefitinib_NN showed_VBD the_DT C_NNP →_NN T_NN mutation_NN at_IN nucleotide_NN 2369_CD in_IN exon_NN 20_CD
          (_( Figure_NN 2_CD C_NNP ,_, lower_JJR panels_NNS ;_: Table_NNP 1_LS )_) ,_, corresponding_JJ to_TO the_DT T_NN 790_CD M_NNP mutation_NN described_VBD above_IN ._.
          There_EX was_VBD no_DT dramatic_JJ change_NN between_IN the_DT two_CD samples_NNS in_IN the_DT ratio_NN of_IN the_DT A_DT :_: G_NNP SNP_NNP at_IN
          position_NN 2361_CD ._. The_DT mutant_JJ 2369_CD T_NN peak_NN was_VBD small_JJ ,_, possibly_RB because_IN gefitinib_NN had_VBD been_VBN
          discontinued_VBN in_IN this_DT patient_NN for_IN 4_CD mo_NN at_IN the_DT time_NN pleural_NN fluid_JJ tumor_NN cells_NNS were_VBD
          collected_VBN ;_: thus_RB ,_, there_EX was_VBD no_DT selective_JJ advantage_NN conferred_VBD upon_IN cells_NNS bearing_VBG the_DT T_NN 790_CD M_NNP
          mutation_NN ._.
          To_TO determine_VB whether_IN the_DT 2369_CD C_NNP →_NN T_NN mutation_NN was_VBD a_DT previously_RB overlooked_VBN 
          EGFR_NNP mutation_NN found_VBD in_IN NSCLCs_NNP ,_, we_PRP re-reviewed_JJ exon_NN 20_CD sequence_NN tracings_NNS
          derived_VBN from_IN analysis_NN of_IN 96_CD fresh-frozen_JJ resected_JJ tumors_NNS [_NN 3_CD ]_NN and_CC 59_CD paraffin-embedded_JJ
          tumors_NNS [_NN 7_CD ]_NN ,_, all_DT of_IN which_WDT were_VBD removed_VBN from_IN patients_NNS prior_RB to_TO treatment_NN with_IN an_DT EGFR_NNP
          tyrosine_NN kinase_NN inhibitor_NN ._. We_PRP did_VBD not_RB detect_VB any_DT evidence_NN of_IN the_DT T_NN 790_CD M_NNP mutation_NN in_IN these_DT
          155_CD tumors_NNS (_( data_NNS not_RB shown_VBN ;_: see_VB Discussion_NNP )_) ._. Collectively_RB ,_, our_PRP$ results_NNS suggest_VBP that_IN the_DT
          T_NN 790_CD M_NNP mutation_NN is_VBZ associated_VBN with_IN lesions_NNS that_WDT progress_NN while_IN on_IN gefitinib_NN or_CC erlotinib_NN ._.
          Moreover_RB ,_, at_IN least_JJS in_IN patients_NNS 1_CD and_CC 2_CD ,_, the_DT subclones_NNS of_IN tumor_NN cells_NNS bearing_VBG this_DT
          mutation_NN probably_RB emerged_VBD between_IN the_DT time_NN of_IN initial_JJ treatment_NN with_IN a_DT tyrosine_NN kinase_NN
          inhibitor_NN and_CC the_DT appearance_NN of_IN drug_NN resistance_NN ._.
          In_IN three_CD additional_JJ patients_NNS (_( case_NN histories_NNS not_RB described_VBD here_RB )_) with_IN lung_NN
          adenocarcinomas_NNS who_WP improved_VBD but_CC subsequently_RB progressed_VBD on_IN therapy_NN with_IN either_DT gefitinib_NN
          or_CC erlotinib_NN ,_, we_PRP examined_VBD DNA_NNP from_IN tumor_NN specimens_NNS obtained_VBN during_IN disease_NN progression_NN ._.
          In_IN all_DT three_CD patients_NNS ,_, we_PRP found_VBD 
          EGFR_NNP mutations_NNS associated_VBN with_IN drug_NN sensitivity_NN (_( all_DT exon_NN 19_CD
          deletions_NNS )_) ._. However_RB ,_, we_PRP did_VBD not_RB find_VB any_DT additional_JJ mutations_NNS in_IN exons_NNS 18_CD to_TO 24_CD of_IN 
          EGFR_NNP ,_, including_VBG the_DT C_NNP →_NN T_NN change_NN at_IN position_NN 2369_CD (_( data_NNS not_RB shown_VBN )_) ._. These_DT
          results_NNS imply_VBP that_IN alternative_JJ mechanisms_NNS of_IN acquired_VBN drug_NN resistance_NN exist_VB ._.
        
        
          Patients_NNS '_POS Progressive_NNP Tumors_NNP Lack_NNP KRAS_NNP Mutations_NNP
          Mutations_NNP in_IN exon_NN 2_CD of_IN 
          KRAS_NNP 2_CD occur_VB in_IN about_IN one-fourth_NN of_IN NSCLCs_NNP ._. Such_JJ mutations_NNS rarely_RB ,_, if_IN
          ever_RB ,_, accompany_VB 
          EGFR_NNP mutations_NNS and_CC are_VBP associated_VBN with_IN primary_JJ resistance_NN to_TO gefitinib_NN
          or_CC erlotinib_NN [_NN 7_CD ]_NN ._. To_TO evaluate_VB the_DT possibility_NN that_IN secondary_JJ 
          KRAS_NNP mutations_NNS confer_VBP acquired_VBN resistance_NN to_TO these_DT drugs_NNS ,_, we_PRP performed_VBD
          mutational_NN profiling_VBG of_IN 
          KRAS_NNP 2_CD exon_NN 2_CD from_IN tumor_NN specimens_NNS from_IN patients_NNS 1_CD to_TO 3_CD ,_, as_RB well_RB as_IN the_DT
          three_CD additional_JJ patients_NNS lacking_VBG evidence_NN of_IN the_DT T_NN 790_CD M_NNP mutation_NN ._. None_NN of_IN the_DT specimens_NNS
          contained_VBD any_DT changes_NNS in_IN 
          KRAS_NNP (_( Table_NNP 1_CD ;_: data_NNS not_RB shown_VBN )_) ,_, indicating_VBG that_IN 
          KRAS_NNP mutations_NNS were_VBD not_RB responsible_JJ for_IN drug_NN resistance_NN and_CC tumor_NN
          progression_NN in_IN these_DT six_CD patients_NNS ._.
        
        
          An_DT Established_VBN NSCLC_NNP Cell_NNP Line_NNP Also_RB Contains_NNP Both_DT T_NN 790_CD M_NNP and_CC L_NNP 858_CD R_NNP Mutations_NNP
          We_PRP profiled_VBN the_DT 
          EGFR_NNP tyrosine_NN kinase_NN domain_NN (_( exons_NNS 18_CD to_TO 24_CD )_) and_CC 
          KRAS_NNP exon_NN 2_CD in_IN eight_CD established_VBN NSCLC_NNP lines_NNS (_( Table_NNP 2_LS )_) ._. Surprisingly_RB ,_,
          one_CD cell_NN line—_NN H_NNP 1975_CD —_NN contained_VBD the_DT same_JJ C_NNP →_NN T_NN mutation_NN at_IN position_NN 2369_CD (_( T_NN 790_CD M_NNP )_) as_IN described_VBN
          above_IN (_( Figure_NN 2_CD D_NNP ,_, lower_JJR panel_NN )_) ._. This_DT cell_NN line_NN had_VBD previously_RB been_VBN shown_VBN by_IN others_NNS to_TO
          contain_VB a_DT 2573_CD T_NN →_NN G_NNP mutation_NN in_IN exon_NN 21_CD (_( L_NNP 858_CD R_NN )_) [_NN 18_CD ]_NN ,_, which_WDT we_PRP confirmed_VBD (_( Figure_NN 2_CD D_NNP ,_, upper_JJ
          panel_NN )_) ;_: in_IN addition_NN ,_, H_NNP 1975_CD was_VBD reported_VBN to_TO be_VB more_RBR sensitive_JJ to_TO gefitinib_NN inhibition_NN than_IN
          other_JJ lung_NN cancer_NN cell_NN lines_NNS bearing_NN wild-type_JJ 
          EGFR_NNP [_NN 18_CD ]_NN ._. Only_RB exons_NNS 19_CD and_CC 21_CD were_VBD apparently_RB examined_VBN in_IN this_DT
          published_JJ study_NN ._.
          In_IN our_PRP$ own_JJ analysis_NN of_IN H_NNP 1975_CD (_( exons_NNS 18_CD to_TO 24_CD )_) ,_, the_DT mutant_JJ 2369_CD T_NN peak_NN resulting_VBG in_IN the_DT
          T_NN 790_CD M_NNP amino_JJ acid_NN substitution_NN was_VBD dominant_JJ ,_, suggesting_VBG an_DT increase_NN in_IN copy_NN number_NN of_IN the_DT
          mutant_JJ allele_NN in_IN comparison_NN to_TO the_DT wild-type_JJ allele_NN ._. The_DT ratio_NN of_IN mutant_JJ to_TO wild-type_JJ
          peaks_NNS was_VBD similar_JJ to_TO that_DT of_IN the_DT mutant_JJ 2573_CD G_NNP (_( corresponding_JJ to_TO the_DT L_NNP 858_CD R_NN amino_JJ acid_NN
          substitution_NN )_) to_TO wild-type_JJ T_NN peaks_NNS (_( Figure_NN 2_CD D_NNP ,_, all_DT panels_NNS )_) ,_, implying_VBG that_IN the_DT T_NN 790_CD M_NNP and_CC
          L_NNP 858_CD R_NN mutations_NNS were_VBD in_IN the_DT same_JJ amplified_VBN allele_NN ._. To_TO further_VB investigate_VB this_DT
          possibility_NN ,_, we_PRP performed_VBD RT-PCR_NNP to_TO generate_VB cDNAs_NNS that_WDT spanned_VBD exon_NN 20_CD of_IN 
          EGFR_NNP and_CC included_VBD sequences_NNS from_IN exon_NN 19_CD and_CC 21_CD ._. PCR_NNP products_NNS were_VBD then_RB
          cloned_VBN ,_, and_CC individual_JJ colonies_NNS were_VBD analyzed_VBN for_IN 
          EGFR_NNP mutations_NNS ._. Sequencing_NNP chromatograms_NNS of_IN DNA_NNP from_IN four_CD of_IN four_CD
          clones_NNS showed_VBD both_DT the_DT 2369_CD C_NNP →_NN T_NN and_CC 2573_CD T_NN →_NN G_NNP mutations_NNS ,_, confirming_VBG that_IN both_DT mutations_NNS
          were_VBD in_IN the_DT same_JJ allele_NN (_( data_NNS not_RB shown_VBN )_) ._.
          Other_JJ NSCLC_NNP cell_NN lines_NNS carried_VBD either_CC 
          EGFR_NNP or_CC 
          KRAS_NNP mutations_NNS ,_, but_CC none_NN had_VBD both_DT (_( Table_NNP 2_LS )_) ._. As_IN reported_VBN ,_, H_NNP 3255_CD
          contained_VBD an_DT L_NNP 858_CD R_NN mutation_NN [_NN 19_CD ]_NN and_CC H_NNP 1650_CD contained_VBD an_DT exon_NN 19_CD deletion_NN [_NN 18_CD ]_NN ._. No_DT other_JJ
          cell_NN lines_NNS analyzed_VBD contained_VBN additional_JJ mutations_NNS in_IN the_DT exons_NNS encoding_VBG the_DT EGFR_NNP
          tyrosine_NN kinase_NN domain_NN ._.
        
        
          A_DT Novel_NNP PCR_NNP Restriction_NNP Fragment_NNP Length_NNP Polymorphism_NNP Assay_NNP Independently_NNP Confirms_NNP
          the_DT Absence_NNP or_CC Presence_NNP of_IN the_DT T_NN 790_CD M_NNP Mutation_NNP
          As_IN stated_VBN above_IN ,_, the_DT mutant_JJ peaks_NNS suggestive_JJ of_IN a_DT T_NN 790_CD M_NNP mutation_NN in_IN exon_NN 20_CD were_VBD small_JJ
          in_IN some_DT sequence_NN chromatograms_NNS ._. To_TO eliminate_VB the_DT possibility_NN that_IN these_DT peaks_NNS were_VBD due_JJ to_TO
          background_NN “ noise_NN ,_,” we_PRP sought_VBD to_TO confirm_VB the_DT presence_NN of_IN the_DT 2369_CD C_NNP →_NN T_NN mutation_NN in_IN
          specific_JJ samples_NNS ,_, by_IN developing_VBG an_DT independent_JJ test_NN ,_, based_VBN on_IN a_DT fluorescence_NN detection_NN
          assay_NN that_WDT takes_VBZ advantage_NN of_IN a_DT PCR_NNP restriction_NN fragment_NN length_NN polymorphism_NN (_( PCR-RFLP_NNP )_)
          generated_VBN by_IN the_DT specific_JJ missense_NN mutation_NN ._. After_IN PCR_NNP amplification_NN with_IN
          exon-_NN 20_CD -_: specific_JJ primers_NNS spanning_VBG nucleotide_NN 2369_CD ,_, wild-type_JJ sequence_NN contains_VBZ specific_JJ
          NlaIII_NNP sites_NNS ,_, which_WDT upon_IN digestion_NN yield_VBP a_DT 106_CD -_: bp_NN product_NN (_( see_VB Methods_NNP ;_: Figure_NN 3_CD A_DT )_) ._.
          Presence_NNP of_IN the_DT mutant_JJ 2369_CD T_NN nucleotide_NN creates_VBZ a_DT new_JJ NlaIII_NNP restriction_NN digest_VB site_NN ,_,
          yielding_VBG a_DT slightly_RB shorter_JJR product_NN (_( 97_CD bp_NN )_) ,_, readily_RB detected_VBN by_IN fluorescent_NN capillary_JJ
          electrophoresis_NNS ._. This_DT test_NN is_VBZ about_IN 2_CD -_: fold_VB more_RBR sensitive_JJ than_IN direct_JJ sequencing_VBG (_( see_VB
          Methods_NNP ;_: data_NNS not_RB shown_VBN )_) ._.
          We_PRP first_RB used_VBN DNA_NNP from_IN the_DT H_NNP 1975_CD cell_NN line_NN (_( which_WDT contains_VBZ both_DT T_NN 790_CD M_NNP and_CC L_NNP 858_CD R_NN
          mutations_NNS )_) to_TO confirm_VB the_DT specificity_NN of_IN the_DT PCR-RFLP_NNP assay_NN ._. As_IN expected_VBN ,_, analysis_NN of_IN
          these_DT cells_NNS produced_VBD both_DT the_DT 97_CD -_: and_CC 106_CD -_: bp_NN fragments_NNS ._. By_IN contrast_NN ,_, analysis_NN of_IN DNA_NNP from_IN
          H_NNP 2030_CD (_( which_WDT contains_VBZ wild-type_JJ 
          EGFR_NNP ;_: Table_NNP 2_LS )_) showed_VBD only_RB the_DT 106_CD -_: bp_NN fragment_NN (_( Figure_NN 3_CD A_DT )_) ._. These_DT data_NNS
          show_VBP that_IN this_DT test_NN can_MD readily_RB indicate_VB the_DT absence_NN or_CC presence_NN of_IN the_DT mutant_JJ allele_NN in_IN
          DNA_NNP samples_NNS ._. However_RB ,_, this_DT test_NN was_VBD only_RB semi-quantitative_JJ ,_, as_IN the_DT ratio_NN of_IN the_DT mutant_JJ
          97_CD -_: bp_NN product_NN versus_CC the_DT wild-type_JJ 106_CD -_: bp_NN product_NN varied_VBD in_IN independent_JJ experiments_NNS from_IN
          approximately_RB 1_CD :_: 1_CD to_TO 2_CD :_: 1_CD ._.
          We_PRP next_RB used_VBD this_DT PCR-RFLP_NNP assay_NN to_TO assess_VB various_JJ patient_NN samples_NNS for_IN the_DT presence_NN of_IN
          the_DT specific_JJ 2369_CD C_NNP →_NN T_NN mutation_NN corresponding_JJ to_TO the_DT T_NN 790_CD M_NNP amino_JJ acid_NN substitution_NN ._. DNA_NNP
          from_IN the_DT progressing_VBG bone_NN and_CC lung_NN lesions_NNS in_IN patient_NN 1_CD produced_VBD both_DT the_DT 97_CD -_: and_CC 106_CD -_: bp_NN
          fragments_NNS ,_, but_CC DNA_NNP from_IN the_DT original_JJ lung_NN tumor_NN did_VBD not_RB (_( Figure_NN 3_CD B_NNP )_) ._. The_DT ratio_NN of_IN mutant_JJ
          to_TO wild-type_JJ products_NNS was_VBD higher_JJR in_IN the_DT cells_NNS from_IN the_DT pleural_NN fluid_JJ ,_, consistent_JJ with_IN the_DT
          higher_JJR peaks_NNS seen_VBN on_IN the_DT chromatograms_NNS from_IN direct_JJ sequencing_VBG of_IN exon_NN 20_CD (_( see_VB Figure_NN 2_CD A_DT )_) ._.
          Likewise_RB ,_, DNA_NNP from_IN progressive_JJ lesions_NNS from_IN patients_NNS 2_CD and_CC 3_CD yielded_VBD both_DT 97_CD -_: and_CC 106_CD -_: bp_NN
          fragments_NNS in_IN the_DT PCR-RFLP_NNP assay_NN (_( Figure_NN 3_CD B_NNP )_) ,_, whereas_IN the_DT pre-treatment_JJ specimens_NNS did_VBD not_RB
          produce_VB the_DT 97_CD -_: bp_NN product_NN ._. Collectively_RB ,_, these_DT data_NNS from_IN an_DT independent_JJ assay_NN confirm_VB
          that_IN the_DT T_NN 790_CD M_NNP mutation_NN was_VBD present_JJ in_IN progressing_VBG lesions_NNS from_IN all_DT three_CD patients_NNS ._. We_PRP
          were_VBD also_RB unable_JJ to_TO detect_VB the_DT T_NN 790_CD M_NNP mutation_NN in_IN any_DT specimens_NNS from_IN the_DT three_CD additional_JJ
          patients_NNS with_IN acquired_VBN resistance_NN that_WDT failed_VBD to_TO demonstrate_VB secondary_JJ mutations_NNS in_IN 
          EGFR_NNP exons_NNS 18_CD to_TO 24_CD by_IN direct_JJ sequencing_VBG (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Biochemical_NNP Properties_NNP of_IN EGFR_NNP Mutants_NNP
          To_TO determine_VB how_WRB the_DT T_NN 790_CD M_NNP mutation_NN would_MD affect_VB EGFR_NNP proteins_NNS already_RB containing_VBG
          mutations_NNS associated_VBN with_IN sensitivity_NN to_TO EGFR_NNP tyrosine_NN kinase_NN inhibitors_NNS ,_, we_PRP introduced_VBD
          the_DT specific_JJ mutation_NN into_IN 
          EGFR_NNP cDNAs_NNS that_IN encoded_JJ the_DT exon_NN 21_CD and_CC 19_CD mutations_NNS found_VBD in_IN patients_NNS
          1_CD and_CC 2_CD ,_, respectively_RB ._. Corresponding_VBG proteins_NNS (_( [_NN i_NNP ]_NN L_NNP 858_CD R_NN and_CC L_NNP 858_CD R_NN plus_CC T_NN 790_CD M_NNP ,_, [_NN ii_NN ]_NN del_FW
          L_NNP 747_CD –_NN E_NNP 749_CD ;_: A_DT 750_CD P_NN and_CC del_FW L_NNP 747_CD –_NN E_NNP 749_CD ;_: A_DT 750_CD P_NN plus_CC T_NN 790_CD M_NNP ,_, and_CC [_NN iii_NN ]_NN wild-type_JJ EGFR_NNP and_CC
          wild-type_JJ EGFR_NNP plus_CC T_NN 790_CD M_NNP )_) were_VBD then_RB produced_VBN by_IN transient_JJ transfection_NN with_IN expression_NN
          vectors_NNS in_IN 293_CD T_NN cells_NNS ,_, which_WDT have_VBP very_RB low_JJ levels_NNS of_IN endogenous_JJ EGFR_NNP [_NN 3_CD ]_NN ._. Various_JJ lysates_NNS
          from_IN cells_NNS that_WDT were_VBD serum-starved_JJ and_CC pre-treated_JJ with_IN gefitinib_NN or_CC erlotinib_NN were_VBD
          analyzed_VBN by_IN immunoblotting_VBG ._. Amounts_NNP of_IN total_JJ EGFR_NNP (_( t-_NN EGFR_NNP )_) were_VBD determined_VBN using_VBG an_DT
          anti-_NN EGFR_NNP monoclonal_NN antibody_NN ,_, and_CC actin_NN served_VBD as_IN an_DT indicator_NN of_IN relative_JJ levels_NNS of_IN
          protein_NN per_IN sample_NN ._. To_TO assess_VB the_DT drug_NN sensitivity_NN of_IN the_DT various_JJ EGFR_NNP kinases_NNS in_IN
          surrogate_JJ assays_NNS ,_, we_PRP used_VBD a_DT Y_NNP 1092_CD -_: phosphate-specific_JJ antibody_NN (_( i_NNP ._. e_SYM ._. ,_, phospho-_NN EGFR_NNP
          [_NN p-_NN EGFR_NNP ]_NN )_) to_TO measure_VB the_DT levels_NNS of_IN “ autophosphorylated_JJ” Tyr-_NNP 1092_CD on_IN EGFR_NNP in_IN relation_NN to_TO
          levels_NNS of_IN t-_NN EGFR_NNP protein_NN ._. We_PRP also_RB assessed_VBD the_DT global_JJ pattern_NN and_CC levels_NNS of_IN induced_VBN
          tyrosine_NN phosphorylation_NN of_IN cell_NN proteins_NNS by_IN using_VBG a_DT generalized_JJ anti-phosphotyrosine_JJ
          reagent_NN (_( RC-_NNP 20_CD )_) ._.
          Gefitinib_NNP inhibited_VBD the_DT activity_NN of_IN wild-type_JJ and_CC L_NNP 858_CD R_NNP EGFRs_NNP progressively_RB with_IN
          increasing_VBG concentrations_NNS of_IN drug_NN ,_, as_IN demonstrated_VBN by_IN a_DT reduction_NN of_IN
          tyrosine-phosphorylated_JJ proteins_NNS (_( Figure_NN 4_CD A_DT )_) and_CC a_DT decrease_NN in_IN p-_NN EGFR_NNP :_: t-_NN EGFR_NNP ratios_NNS
          (_( Figure_NN 4_CD B_NNP )_) ._. By_IN contrast_NN ,_, wild-type_JJ and_CC mutant_JJ EGFRs_NNP containing_VBG the_DT T_NN 790_CD M_NNP mutation_NN did_VBD
          not_RB display_VB a_DT significant_JJ change_NN in_IN either_DT phosphotyrosine_NN induction_NN or_CC p-_NN EGFR_NNP :_: t-_NN EGFR_NNP
          ratios_NNS (_( Figure_NN 4_CD A_DT and_CC 4_CD B_NNP )_) ._. Similar_JJ results_NNS were_VBD obtained_VBN using_VBG erlotinib_NN against_IN
          wild-type_JJ and_CC del_FW E_NNP 747_CD –_NN L_NNP 747_CD ;_: A_DT 750_CD P_NN EGFRs_NNP in_IN comparison_NN to_TO the_DT corresponding_JJ mutants_NNS
          containing_VBG the_DT T_NN 790_CD M_NNP mutation_NN (_( Figure_NN 4_CD C_NNP )_) ._. These_DT results_NNS suggest_VBP that_IN the_DT T_NN 790_CD M_NNP mutation_NN
          may_MD impair_VB the_DT ability_NN of_IN gefitinib_NN or_CC erlotinib_NN to_TO inhibit_VB EGFR_NNP tyrosine_NN kinase_NN
          activity_NN ,_, even_RB in_IN EGFR_NNP mutants_NNS (_( i_NNP ._. e_SYM ._. ,_, L_NNP 858_CD R_NN or_CC an_DT exon_NN 19_CD deletion_NN )_) that_WDT are_VBP clinically_RB
          associated_VBN with_IN drug_NN sensitivity_NN ._.
        
        
          Resistance_NNP of_IN a_DT NSCLC_NNP Cell_NNP Line_NNP Harboring_NNP Both_DT T_NN 790_CD M_NNP and_CC L_NNP 858_CD R_NNP Mutations_NNP to_TO
          Gefitinib_NNP or_CC Erlotinib_NNP
          To_TO further_VB explore_VB the_DT functional_JJ consequences_NNS of_IN the_DT T_NN 790_CD M_NNP mutation_NN ,_, we_PRP determined_VBD
          the_DT sensitivity_NN of_IN various_JJ NSCLC_NNP cells_NNS lines_NNS grown_VBN in_IN the_DT presence_NN of_IN either_DT gefitinib_NN or_CC
          erlotinib_NN ,_, using_VBG an_DT assay_NN based_VBN upon_IN Calcein_NNP AM_NNP ._. Uptake_NNP and_CC retention_NN of_IN this_DT fluorogenic_JJ
          esterase_NN substrate_NN by_IN vehicle-_NN versus_CC drug-treated_JJ live_VB cells_NNS allows_VBZ for_IN a_DT comparison_NN of_IN
          relative_JJ cell_NN viability_NN among_IN cell_NN lines_NNS [_NN 20_CD ]_NN ._. The_DT H_NNP 3255_CD cell_NN line_NN ,_, which_WDT harbors_VBZ the_DT
          L_NNP 858_CD R_NN mutation_NN and_CC no_DT other_JJ 
          EGFR_NNP TK_NNP domain_NN mutations_NNS (_( Table_NNP 2_LS )_) ,_, was_VBD sensitive_JJ to_TO treatment_NN with_IN
          gefitinib_NN ,_, with_IN an_DT IC_NNP
          50_CD of_IN about_IN 0_CD ._. 01_CD μmol_NN (_( Figure_NN 5_LS )_) ._. By_IN contrast_NN ,_, the_DT H_NNP 1975_CD cell_NN line_NN ,_,
          which_WDT contains_VBZ both_DT L_NNP 858_CD R_NN and_CC T_NN 790_CD M_NNP mutations_NNS (_( Table_NNP 2_LS )_) ,_, was_VBD approximately_RB 100_CD -_: fold_VB less_RBR
          sensitive_JJ to_TO drug_NN ,_, with_IN an_DT IC_NNP
          50_CD of_IN about_IN 1_CD μmol_NN (_( Figure_NN 5_LS )_) ._. In_IN fact_NN ,_, the_DT sensitivity_NN of_IN H_NNP 1975_CD cells_NNS
          was_VBD more_RBR similar_JJ to_TO that_DT of_IN H_NNP 2030_CD ,_, which_WDT contains_VBZ wild-type_JJ 
          EGFR_NNP (_( exons_NNS 18_CD to_TO 24_CD )_) and_CC mutant_JJ 
          KRAS_NNP (_( Figure_NN 5_LS )_) ._. Very_RB similar_JJ results_NNS were_VBD obtained_VBN with_IN erlotinib_NN
          (_( Figure_NNP S_NNP 3_LS )_) ._.
        
      
      
        Discussion_NNP
        Specific_JJ mutations_NNS in_IN the_DT tyrosine_NN kinase_NN domain_NN of_IN 
        EGFR_NNP are_VBP associated_VBN with_IN sensitivity_NN to_TO either_CC gefitinib_NN or_CC erlotinib_NN ,_,
        but_CC mechanisms_NNS of_IN acquired_VBN resistance_NN have_VBP not_RB yet_RB been_VBN reported_VBN ._. Based_VBN upon_IN analogous_JJ
        studies_NNS in_IN other_JJ diseases_NNS with_IN another_DT kinase_NN inhibitor_NN ,_, imatinib_NN ,_, a_DT single_JJ amino_JJ acid_NN
        substitution_NN from_IN threonine_NN to_TO methionine_NN at_IN position_NN 790_CD in_IN the_DT wild-type_JJ EGFR_NNP kinase_NN
        domain_NN was_VBD predicted_VBN to_TO lead_VB to_TO drug_NN resistance_NN ,_, even_RB before_IN the_DT association_NN of_IN exon_NN 19_CD and_CC
        21_CD mutations_NNS of_IN 
        EGFR_NNP with_IN drug_NN responsiveness_NNS in_IN NSCLC_NNP was_VBD reported_VBN ._. The_DT T_NN 790_CD M_NNP mutation_NN
        was_VBD shown_VBN in_IN vitro_NN in_IN the_DT context_NN of_IN wild-type_JJ EGFR_NNP to_TO confer_VB resistance_NN to_TO gefitinib_NN [_NN 21_CD ]_NN
        and_CC a_DT related_VBN quinazoline_NN inhibitor_NN ,_, PD_NNP 153035_CD [_NN 22_CD ]_NN ._.
        We_PRP show_VBP here_RB ,_, through_IN molecular_JJ analysis_NN of_IN tumor_NN material_NN from_IN three_CD patients_NNS and_CC one_CD
        NSCLC_NNP cell_NN line_NN ,_, as_RB well_RB as_IN additional_JJ biochemical_JJ studies_NNS ,_, that_WDT acquired_VBD clinical_JJ drug_NN
        resistance_NN to_TO gefitinib_NN or_CC erlotinib_NN is_VBZ indeed_RB associated_VBN with_IN the_DT T_NN 790_CD M_NNP mutation_NN ._.
        Importantly_NNP ,_, we_PRP find_VBP that_IN the_DT T_NN 790_CD M_NNP mutation_NN confers_VBZ drug_NN resistance_NN not_RB just_RB to_TO wild-type_JJ
        EGFR_NNP but_CC also_RB to_TO mutant_JJ EGFRs_NNP associated_VBN with_IN clinical_JJ responsiveness_NNS to_TO EGFR_NNP tyrosine_NN
        kinase_NN inhibitors_NNS [_NN 1_CD ,_, 2_CD ,_, 3_CD ]_NN ._. Our_PRP$ results_NNS further_JJ demonstrate_VB that_IN an_DT analogous_JJ mechanism_NN of_IN
        acquired_VBN resistance_NN exists_VBZ for_IN imatinib_NN and_CC EGFR_NNP tyrosine_NN kinase_NN inhibitors_NNS (_( Table_NNP 3_LS )_) ,_,
        despite_IN the_DT fact_NN that_IN the_DT various_JJ agents_NNS target_VBP different_JJ kinases_NNS in_IN distinct_JJ diseases_NNS ._.
        In_IN tumors_NNS from_IN patients_NNS not_RB treated_VBN with_IN either_DT gefitinib_NN or_CC erlotinib_NN ,_, the_DT 2369_CD C_NNP →_NN T_NN
        mutation_NN (_( T_NN 790_CD M_NNP )_) appears_VBZ to_TO be_VB extremely_RB rare_JJ ._. We_PRP have_VBP not_RB identified_VBN this_DT mutation_NN in_IN 155_CD
        tumors_NNS (_( see_VB above_IN )_) ,_, and_CC among_IN nearly_RB 1_CD ,_, 300_CD lung_NN cancers_NNS in_IN which_WDT analysis_NN of_IN 
        EGFR_NNP exons_NNS 18_CD to_TO 21_CD has_VBZ been_VBN performed_VBN [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ]_NN ,_, only_RB one_CD tumor_NN
        (_( which_WDT also_RB harbored_JJ an_DT L_NNP 858_CD R_NN mutation_NN )_) was_VBD reported_VBN to_TO contain_VB the_DT T_NN 790_CD M_NNP mutation_NN ._. Whether_IN
        the_DT patient_NN from_IN which_WDT this_DT tumor_NN was_VBD resected_JJ had_VBD received_VBN gefitinib_NN or_CC erlotinib_NN is_VBZ
        unclear_JJ ,_, and_CC the_DT report_NN did_VBD not_RB note_VB an_DT association_NN with_IN acquired_VBN resistance_NN to_TO either_CC drug_NN
        [_NN 5_CD ]_NN ._.
        How_WRB tumor_NN cells_NNS bearing_VBG the_DT T_NN 790_CD M_NNP mutation_NN emerge_VB within_IN gefitinib-_NN or_CC erlotinib-treated_JJ
        patients_NNS is_VBZ a_DT matter_NN of_IN investigation_NN ._. Subclones_NNP bearing_VBG this_DT mutation_NN could_MD arise_VB de_IN novo_NN
        during_IN treatment_NN
        ._. However_RB ,_, based_VBN upon_IN analogous_JJ studies_NNS in_IN CML_NNP ,_, it_PRP is_VBZ also_RB possible_JJ that_IN
        NSCLC_NNP subclones_NNS bearing_VBG this_DT secondary_JJ mutation_NN pre-exist_JJ within_IN the_DT primary_JJ tumor_NN clone_NN in_IN
        individual_JJ patients_NNS ,_, albeit_IN at_IN low_JJ frequency_NN [_NN 23_CD ]_NN ._. In_IN either_DT scenario_NN ,_, treatment_NN with_IN
        gefitinib_NN or_CC erlotinib_NN subsequently_RB allows_VBZ these_DT resistant_JJ subclones_NNS to_TO become_VB apparent_JJ ,_,
        because_IN most_JJS cells_NNS bearing_VBG sensitivity-conferring_JJ mutations_NNS die_VBP ,_, while_IN cells_NNS with_IN the_DT T_NN 790_CD M_NNP
        mutation_NN persist_VB ._.
        From_IN analysis_NN of_IN the_DT crystal_NN structure_NN of_IN the_DT EGFR_NNP kinase_NN domain_NN bound_VBN to_TO erlotinib_NN ,_, it_PRP
        is_VBZ has_VBZ been_VBN shown_VBN that_IN the_DT wild-type_JJ threonine_NN residue_NN at_IN position_NN 790_CD is_VBZ located_VBN in_IN the_DT
        hydrophobic_JJ ATP-binding_NNP pocket_NN of_IN the_DT catalytic_JJ region_NN ,_, where_WRB it_PRP forms_VBZ a_DT critical_JJ hydrogen_NN
        bond_NN with_IN the_DT drug_NN [_NN 24_CD ]_NN ._. The_DT related_VBN compound_NN ,_, gefitinib_NN ,_, is_VBZ predicted_VBN to_TO interact_NN with_IN
        this_DT threonine_NN residue_NN as_RB well_RB ._. Substitution_NNP of_IN the_DT threonine_NN at_IN position_NN 790_CD by_IN a_DT larger_JJR
        residue_NN like_IN methionine_NN would_MD probably_RB result_VB in_IN steric_JJ clash_NN with_IN the_DT aromatic_JJ moieties_NNS on_IN
        these_DT two_CD drugs_NNS [_NN 25_CD ]_NN ._. By_IN contrast_NN ,_, ATP_NNP would_MD likely_JJ not_RB depend_VB on_IN the_DT accessibility_NN of_IN the_DT
        same_JJ hydrophobic_JJ cavity_NN and_CC is_VBZ therefore_RB probably_RB not_RB affected_VBN by_IN the_DT incorporation_NN of_IN a_DT
        bulky_JJ methionine_NN side_NN chain_NN [_NN 25_CD ]_NN ._. Consistent_NNP with_IN this_DT ,_, the_DT T_NN 790_CD M_NNP mutation_NN has_VBZ been_VBN shown_VBN
        not_RB to_TO abrogate_NN the_DT catalytic_JJ activity_NN of_IN wild-type_JJ EGFR_NNP [_NN 22_CD ]_NN ._.
        The_DT T_NN 790_CD M_NNP mutation_NN could_MD also_RB affect_VB the_DT kinase_NN activity_NN or_CC alter_VB the_DT substrate_NN
        specificity_NN of_IN mutant_JJ EGFRs_NNP ,_, such_JJ that_IN a_DT proliferative_JJ advantage_NN would_MD be_VB conferred_VBD upon_IN
        cells_NNS bearing_VBG the_DT mutation_NN ._. Consistent_NNP with_IN this_DT ,_, the_DT H_NNP 1975_CD NSCLC_NNP cell_NN line_NN reported_VBD here_RB
        to_TO contain_VB both_DT T_NN 790_CD M_NNP and_CC L_NNP 858_CD R_NN did_VBD not_RB to_TO our_PRP$ knowledge_NN undergo_VBP any_DT prior_JJ treatment_NN with_IN
        gefitinib_NN or_CC erlotinib_NN ;_: the_DT doubly_RB mutated_VBN cells_NNS must_MD have_VB become_VBN dominant_JJ over_IN time_NN
        through_IN multiple_JJ passages_NNS in_IN vitro_NN ._. This_DT scenario_NN could_MD explain_VB the_DT seemingly_RB contradictory_JJ
        report_NN by_IN others_NNS who_WP found_VBD the_DT H_NNP 1975_CD cell_NN line_NN to_TO be_VB highly_RB sensitive_JJ to_TO gefitinib_NN [_NN 18_CD ]_NN ;_:
        our_PRP$ H_NNP 1975_CD cells_NNS could_MD represent_VB a_DT subclone_NN that_WDT emerged_VBD over_IN time_NN ._. Analysis_NNP of_IN earlier_JJR
        passages_NNS of_IN H_NNP 1975_CD cells_NNS for_IN the_DT T_NN 790_CD M_NNP mutation_NN would_MD be_VB informative_JJ in_IN this_DT regard_NN ._.
        Recently_RB ,_, new_JJ small-molecule_JJ inhibitors_NNS have_VBP been_VBN identified_VBN that_WDT retain_VBP activity_NN
        against_IN the_DT majority_NN of_IN imatinib-resistant_JJ BCR-ABL_NNP mutants_NNS ._. The_DT new_JJ drugs_NNS bind_NN to_TO ABL_NNP in_IN an_DT
        “ open_JJ” conformation_NN ,_, as_IN opposed_VBN to_TO imatinib_NN ,_, which_WDT binds_NNS ABL_NNP in_IN a_DT “ closed_VBN” conformation_NN
        [_NN 12_CD ,_, 13_CD ]_NN ._. Analogously_NNP ,_, it_PRP may_MD be_VB possible_JJ to_TO find_VB EGFR_NNP tyrosine_NN kinase_NN inhibitors_NNS that_WDT bind_NN
        to_TO the_DT EGFR_NNP kinase_NN domain_NN in_IN different_JJ ways_NNS than_IN gefitinib_NN and_CC erlotinib_NN ._. For_IN example_NN ,_, the_DT
        crystal_NN structure_NN of_IN another_DT EGFR_NNP inhibitor_NN ,_, lapatinib_NN (_( GW_NNP 572016_CD )_) ,_, was_VBD recently_RB solved_VBN
        bound_VBN to_TO EGFR_NNP [_NN 26_CD ]_NN ._. This_DT study_NN revealed_VBD that_IN the_DT quinazoline_NN rings_NNS of_IN erlotinib_NN and_CC
        lapatinib_NN interact_NN differently_RB with_IN the_DT EGFR_NNP kinase_NN domain_NN ,_, suggesting_VBG that_IN while_IN the_DT T_NN 790_CD M_NNP
        mutation_NN may_MD affect_VB inhibition_NN by_IN erlotinib_NN and_CC gefitinib_NN ,_, it_PRP may_MD not_RB affect_VB inhibition_NN of_IN
        EGFR_NNP by_IN compounds_NNS similar_JJ to_TO lapatinib_NN ._. To_TO our_PRP$ knowledge_NN ,_, no_DT NSCLC_NNP patient_NN who_WP initially_RB
        responded_VBD to_TO but_CC then_RB progressed_VBD on_IN either_DT gefitinib_NN or_CC erlotinib_NN has_VBZ yet_RB been_VBN treated_VBN with_IN
        lapatinib_NN ._.
        In_IN some_DT of_IN the_DT patient_NN specimens_NNS analyzed_VBD ,_, the_DT actual_JJ sequencing_VBG peaks_NNS demonstrating_VBG the_DT
        T_NN 790_CD M_NNP mutation_NN were_VBD smaller_JJR than_IN originally_RB anticipated_VBN ._. These_DT results_NNS differ_VBP from_IN those_DT of_IN
        acquired_VBN resistance_NN mutation_NN in_IN CML_NNP [_NN 10_CD ]_NN ,_, GIST_NNP [_NN 15_CD ,_, 27_CD ]_NN ,_, and_CC HES_NNP [_NN 16_CD ]_NN ._. However_RB ,_, in_IN contrast_NN
        to_TO all_DT of_IN these_DT diseases_NNS ,_, in_IN which_WDT tumor_NN cells_NNS are_VBP readily_RB accessible_JJ ,_, lung-cancer-related_JJ
        tumors_NNS are_VBP more_RBR difficult_JJ to_TO access_VB ,_, as_IN illustrated_VBN by_IN the_DT limited_JJ manner_NN in_IN which_WDT we_PRP were_VBD
        able_JJ to_TO obtain_VB tumor_NN cells_NNS from_IN various_JJ sites_NNS of_IN disease_NN (_( see_VB Figure_NN 1_LS )_) ._. Moreover_RB ,_,
        re-biopsy_JJ of_IN patients_NNS with_IN lung_NN cancer_NN is_VBZ not_RB routinely_RB performed_VBN ._. The_DT use_NN of_IN position_NN
        emission_NN tomography_NN scans_VBZ to_TO identify_VB the_DT most_RBS metabolically_RB active_JJ lesions_NNS for_IN biopsy_NN
        could_MD possibly_RB circumvent_VB this_DT factor_NN in_IN the_DT future_NN ,_, as_RB long_RB as_IN such_JJ lesions_NNS are_VBP
        resectable_JJ ._. Additionally_RB ,_, as_IN more_RBR molecularly_RB tailored_VBN treatment_NN options_NNS become_VBP available_JJ
        for_IN lung_NN cancer_NN ,_, re-biopsy_JJ of_IN progressive_JJ sites_NNS of_IN disease_NN should_MD become_VB a_DT standard_JJ
        procedure_NN ,_, especially_RB for_IN patients_NNS on_IN clinical_JJ trials_NNS of_IN targeted_VBN agents_NNS ._.
        Since_IN tumor_NN specimens_NNS from_IN three_CD additional_JJ patients_NNS with_IN acquired_VBN resistance_NN to_TO EGFR_NNP
        tyrosine_NN kinase_NN inhibitors_NNS did_VBD not_RB demonstrate_VB the_DT T_NN 790_CD M_NNP mutation_NN ,_, this_DT specific_JJ lesion_NN
        does_VBZ not_RB account_VB for_IN all_DT mechanisms_NNS of_IN acquired_VBN resistance_NN to_TO gefitinib_NN or_CC erlotinib_NN ._. Given_VBN
        the_DT paradigm_NN established_VBN with_IN imatinib_NN ,_, other_JJ drug-resistance_JJ mutations_NNS in_IN 
        EGFR_NNP ,_, either_CC within_IN or_CC outside_IN the_DT tyrosine_NN kinase_NN domain_NN ,_, are_VBP likely_JJ to_TO
        exist_VB ._. It_PRP is_VBZ also_RB possible_JJ that_IN 
        EGFR_NNP amplification_NN itself_PRP plays_VBZ a_DT role_NN in_IN acquired_VBN resistance_NN ,_, since_IN
        imatinib-resistant_JJ clones_NNS have_VBP been_VBN shown_VBN to_TO lack_NN resistance_NN mutations_NNS but_CC contain_VB
        amplified_VBN copies_NNS of_IN 
        BCR-ABL_NNP [_NN 11_CD ,_, 28_CD ]_NN ._. Nonetheless_RB ,_, studies_NNS presented_VBN here_RB provide_VB a_DT basis_NN for_IN
        the_DT rational_JJ development_NN of_IN “ second_JJ generation_NN” kinase_NN inhibitors_NNS for_IN use_NN in_IN NSCLC_NNP ._.
      
      
        Supporting_VBG Information_NNP
        
          Accession_NNP Numbers_NNPS
          The_DT LocusLink_NNP (_( http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN LocusLink_NNP /_NN )_) accession_NN number_NN for_IN the_DT 
          KRAS_NNP 2_CD sequence_NN discussed_VBN in_IN this_DT paper_NN is_VBZ 3845_CD ;_: the_DT GenBank_NNP
          (_( http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN Genbank_NNP /_NN )_) accession_NN number_NN for_IN the_DT 
          KRAS_NNP 2_CD sequence_NN discussed_VBN in_IN this_DT paper_NN is_VBZ NT_NNP __NN 009714_CD ._. 16_CD ._. Reference_NNP 
          EGFR_NNP sequence_NN was_VBD obtained_VBN from_IN LocusLink_NNP accession_NN number_NN 1956_CD and_CC
          GenBank_NNP accession_NN number_NN NT_NNP __NN 033968_CD ._.
        
      
    
  
